MYH9-related disease (MYH9-RD) is a rare autosomal dominant disease caused by mutation of MYH9, the gene encoding for the heavy chain of non-muscle myosin IIA (NMMHC-IIA). MYH9-RD patients have macrothrombocytopenia and granulocyte inclusions (pathognomonic sign of the disease) containing wild-type and mutant NMMHC-IIA. During life they might develop sensorineural hearing loss, cataract, glomerulonephritis, and elevation of liver enzymes. One of the MYH9 mutations, p.R705H, was previously reported to be associated with DFNA17, an autosomal dominant non-syndromic sensorineural hearing loss without any other features associated. We identified the same mutation in two unrelated families, whose four affected individuals had not only hearing impairment but also thrombocytopenia, giant platelets, leukocyte inclusions, as well as mild to moderate elevation of some liver enzymes. Our data suggest that DFNA17 should not be a separate genetic entity but part of the wide phenotypic spectrum of MYH9-RD characterized by congenital hematological manifestations and variable penetrance and expressivity of the extra-hematological features.

R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17

DE ROCCO, DANIELA;SAVOIA, ANNA
2015-01-01

Abstract

MYH9-related disease (MYH9-RD) is a rare autosomal dominant disease caused by mutation of MYH9, the gene encoding for the heavy chain of non-muscle myosin IIA (NMMHC-IIA). MYH9-RD patients have macrothrombocytopenia and granulocyte inclusions (pathognomonic sign of the disease) containing wild-type and mutant NMMHC-IIA. During life they might develop sensorineural hearing loss, cataract, glomerulonephritis, and elevation of liver enzymes. One of the MYH9 mutations, p.R705H, was previously reported to be associated with DFNA17, an autosomal dominant non-syndromic sensorineural hearing loss without any other features associated. We identified the same mutation in two unrelated families, whose four affected individuals had not only hearing impairment but also thrombocytopenia, giant platelets, leukocyte inclusions, as well as mild to moderate elevation of some liver enzymes. Our data suggest that DFNA17 should not be a separate genetic entity but part of the wide phenotypic spectrum of MYH9-RD characterized by congenital hematological manifestations and variable penetrance and expressivity of the extra-hematological features.
File in questo prodotto:
File Dimensione Formato  
125 postprint.pdf

Open Access dal 01/06/2016

Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 870.28 kB
Formato Adobe PDF
870.28 kB Adobe PDF Visualizza/Apri
125 Verver_et_al-2015-Clinical_Genetics.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Digital Rights Management non definito
Dimensione 302.55 kB
Formato Adobe PDF
302.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
cge12438-sup-0001-FigureS1.pdf

Accesso chiuso

Descrizione: pdf supporting information 1
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 264.23 kB
Formato Adobe PDF
264.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
cge12438-sup-0002-FigureS2.pdf

Accesso chiuso

Descrizione: pdf supporting information 2
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 194.23 kB
Formato Adobe PDF
194.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2807133
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact